The endogenous GC levels were further confirmed to stratify patients with different prognoses in terms of PFS and OS in patients with different tumor type (Figure 3C for NSCLC, and Figure 3D for gastric cancer) or different anti-cancer treatment (see Supplemental Figure 1). This evidence concerns the gene GC and non-small cell lung carcinoma.